Frontlight ResearchEarly access
CompletedPhase 2
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Key facts
- Who runs it
- Tarsus Pharmaceuticals, Inc.
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 30 people enrolled
- Started
- 12 Dec 2022
- Ended
- 26 Jun 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Low Dose TP-05
- High Dose TP-05
- Placebo Comparator
- Record updated
- 19 September 2024
Who can take part
- Age
- 18 years to 59 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Participant must be 18 to 59 years of age inclusive, at the time of signing the informed consent
- Participants who are overtly healthy as determined by medical evaluation including having no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination
- Participants who are non- or ex-smokers
- Willingness to comply with all study procedures and availability for the duration of the study
- BMI within the range 18 - 32 kg/m2
- Willingness to comply with contraceptive requirements
- Capable of giving signed informed consent
Who cannot take part
- Any clinically significant illness in the 28 days prior to study treatment administration
- Use of any non-prescription or prescription drugs (with the exception of hormonal contraceptives, hormone replacement therapy, acetaminophen) in the 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to study treatment administration
- Use of St. John's wort in the 28 days prior to study treatment administration
- Intake of lotilaner in the 6 months prior to study treatment administration
- Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening
- History of live attenuated vaccine within 4 weeks prior to randomization or requirement to receive these vaccinations at any time during the study
- Blood donation of approximately 500 mL within 56 days prior to Screening
- Plasma donation within 7 days prior to Screening
- History of significant hypersensitivity to lotilaner or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- Presence or history of significant gastrointestinal, metabolic, liver or kidney disease, or surgery that may affect drug bioavailability (excluding appendectomy)
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
- Have a history of malignancy (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma
- Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse
- Known history of chronic infectious disease
- History of allergy to surgical tape, hydrocolloid, or dressing
- History of severe reactions to tick bites (granuloma or systemic reactions)
- Female who is pregnant according to the serum pregnancy test at Screening or prior to study treatment administration
- Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of the Investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
- Female who is lactating at Screening
- Presence of clinically significant ECG abnormalities at Screening, as defined by the Investigator
Where in United States
- Tufts University School of MedicineBoston, United States
About the trial
What the trial wants to find out
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.
The 3 groups in the trial
- Low Dose of TP-05 (lotilaner)Treatment being tested
Single Oral Low Dose of TP-05 tablet.
Treatment: Low Dose TP-05
- High Dose of TP-05 (lotilaner)Treatment being tested
Single Oral High Dose of TP-05 tablet.
Treatment: High Dose TP-05
- PlaceboPlacebo, for comparison
Single Oral Dose of placebo tablet.
Treatment: Placebo Comparator
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Single-Center, Human Tick Kill Proof-of-Concept Study Evaluating the Safety, Tolerability, and Whole Blood Concentration of TP-05 (lotilaner) in Healthy Volunteers
- Record updated
- 19 September 2024